Acetylsalicylic acid Not Yet Recruiting Phase 2 Trials for Primary Myelofibrosis / Myeloproliferative Neoplasms / Polycythemia Vera (PV) / Venous Thromboembolism / Essential Thrombocythemia (ET) / JAK2 Mutation Prevention

IndicationsStatusPurposePhase
Not Yet RecruitingPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT04243122Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients